Ontology highlight
ABSTRACT:
SUBMITTER: Li BT
PROVIDER: S-EPMC6366814 | biostudies-literature | 2018 Aug
REPOSITORIES: biostudies-literature
Li Bob T BT Shen Ronglai R Buonocore Darren D Olah Zachary T ZT Ni Ai A Ginsberg Michelle S MS Ulaner Gary A GA Offin Michael M Feldman Daniel D Hembrough Todd T Cecchi Fabiola F Schwartz Sarit S Pavlakis Nick N Clarke Stephen S Won Helen H HH Brzostowski Edyta B EB Riely Gregory J GJ Solit David B DB Hyman David M DM Drilon Alexander A Rudin Charles M CM Berger Michael F MF Baselga Jose J Scaltriti Maurizio M Arcila Maria E ME Kris Mark G MG
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20180710 24
Purpose Human epidermal growth factor receptor 2 ( HER2, ERBB2)-activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. Patients and Methods Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation C ...[more]